Financial intelligence for Asia's healthcare markets
Remember me:

News articles    

Healthcare business Max India has received shareholder approval to merge its healthcare assets into Max Healthcare and demerge other residual businesses into Advaita, a wholly-owned subsidiary of Max India.
Singapore-based digital healthcare platform MyDoc has signed a deal with Hanoi-headquartered Baoviet Group Insurance to offer a cashless digitally integrated clinic service to its health insurance policyholders.
Interventional medical products provider Peijia Medical Co has raised $100 million in a Series C funding round led by its existing investor, venture capital firm Matrix Partners China.
English-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca has announced three large-scale initiatives in China to advance global research and development for new medicines.
Global healthcare company MORE Health has agreed a collaboration with Japan’s Integrity Healthcare, giving international patients access to Integrity Healthcare’s physicians and services.
The Malaysia Healthcare Travel Council says the country’s hospital receipts will be in excess of 2 billion ringgit next year, fuelled by international healthcare tourists expected to number around two million.
The medical health tourism industry in Malaysia could be affected if the government introduces the medicine price control mechanism for private healthcare operators.
Hong Kong-headquartered SinoMab BioScience is looking to raise HK$1.75 billion ($223 million) from an initial public offering.
Fountain Medical Development, a Chinese clinical-stage contract research organisation offering services to pharmaceutical and medical device companies, has raised $62 million in Series D funding.
Chinese biotechnology company Denovo Biopharma, which provides a biomarker solution to personalise drug development, has raised ¥300 million ($42.6 million) in Series B funding.

Subscribe to our news RSS feed Get the RSS for HealthInvestor Asia




The IPO market in Hong Kong is hotting up again and it looks as though 2019 is going to be as busy with biotech company floats as last year was.



HealthInvestor Asia twitter feed


HealthInvestor UK